Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2C9 11/11 genotype on initial and long-term warfarin dose requirement and therapeutic response.

Pharmacogenomics - 1 Dec 2020

Quinn Alison Lh, Bhat Shubha, Lee James C

Abstract excerpt

The warfarin dose requirement and therapeutic response of a 42-year-old African-American male with genotype CYP2C9 *11/*11, VKORC1 -1639GG and CYP4F2 433Val/Val anticoagulated for ischemic stroke is described herein. Warfarin was dosed according to the institution's personalized medicine program recommendations of a 10 mg mini-load dose, followed by dose decreases to 4-6 mg/day through discharge. Stable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ambulatory Care
Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypertension

Share to International Normalized Ratio

Share to Ischemic Stroke

Share to Precision Medicine

Share to Warfarin

Source

Identifiers

PMID: 33350885
DOI: 10.2217/pgs-2020-0125

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2C9 *11/*11 genotype on initial and long-term warfarin dose requirement and therapeutic response.PMID 33350885Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement.Semantic proximity Read ↗

Warfarin dose requirements in a patient with the CYP2C9*14 allele.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.Semantic proximity Read ↗

CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic DosingSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Semantic proximity Read ↗

Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients.Semantic proximity Read ↗

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.Semantic proximity Read ↗

Efficacy of Warfarin Therapy Guided by Pharmacogenetics: A Real-world Investigation Among Han Taiwanese.Semantic proximity Read ↗

Genetic and clinical predictors of warfarin dose requirements in African Americans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.